v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Nov. 08, 2024
Dec. 31, 2024
Jun. 30, 2024
Mar. 31, 2026
Mar. 31, 2025
Oct. 31, 2025
Nov. 12, 2024
Nov. 11, 2024
May 13, 2024
Reverse stock split 1-for-10 reverse stock split                
Common stock, par value $ 0.001     $ 0.001 $ 0.001        
Preferred stock, par value $ 0.001                
Cash equivalents       $ 0 $ 0        
Dilutive shares       1,000,000          
Increase in in-process research and development         15,457,444        
Deferred tax liabilities, in-process research and development         3,449,767        
Increase in total consideration paid         450,000        
Goodwill impairment charges       $ 0 0        
Indefinite-lived intangible assets, impairment charges       0 0        
Cash       20,878 19,914        
Accounts payable and accrued expenses       15,000          
Orocidin A/S [Member]                  
Ownership percentage   100.00%             95.00%
Novi Thera [Member]                  
Ownership percentage           50.10%      
Orocidin A/S [Member]                  
Ownership percentage acquired             5.00% 5.34% 95.00%
Orocidin A/S [Member]                  
Revenue recognized         2,500        
Subsidiary Issuer [Member] | Orocidin A/S [Member]                  
Revenue recognized     $ 0            
Subsidiary Issuer [Member] | Bio-Convert A/S [Member]                  
Revenue recognized   $ 0              
Bio-Convert A/S [Member]                  
Revenue recognized         2,500        
Bio Convert [Member]                  
Increase in in-process research and development         26,475,819        
Deferred tax liabilities, in-process research and development         $ 5,868,647        
Novi Thera [Member]                  
Cash       4,616          
Prepaid expenses and other current assets       5,707          
Other assets       12,556          
Accounts payable and accrued expenses       $ 91,422          
Warrant [Member]                  
Dilutive shares       75,000 900,000        
Share-Based Payment Arrangement, Option [Member]                  
Dilutive shares       925,000